ClinicalTrials.gg
RecruitingNCT06753006Updated Jan 1, 2025

Research on the Effectiveness of Neurorehabilitation After Stroke

An interventional study of Neurorehabilitation simulator and Standard course in Stroke, Stroke Acute and Stroke with Hemiparesis, sponsored by Neurotechnika. Recruiting at 1 site in Russian Federation. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-01-01.

Primary conditionIschemic StrokeRegistry: StrokeReclassifiedWhy we changed it
Registry
Stroke — the first condition term the registry derived for this study.
ClinicalTrials.gg
Ischemic Stroke
Why
  1. The study's listed conditions name Ischemic Stroke, a narrower term within Stroke.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Neurotechnika · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled Aug 2024, registered Dec 2024).
  • Started Aug 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Ischemic Stroke with a site in Russian Federation — 4 open to participants now, 4 under way, none of them phase 3. Ischemic Stroke · Russian Federation.

Planned enrollment
13th of 19
44 · median 120
Started
2024
with 2 others
No phase
4 of 26
2 open now
Registered
25th of 26
by date

Among the 26 studies in Ischemic Stroke with a site in Russian Federation, this one is the 13th largest by planned enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2024, is one of 4 with no phase, and was the 25th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

4 of the 26 studies in Ischemic Stroke with a site in Russian Federation are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Ischemic Stroke with a site in Russian Federation, or all of them as a file.
02

Study summary

This clinical trial aims to investigate the effectiveness of a novel neurorehabilitation technology for treating stroke in adults. The study will evaluate a simulator that combines robotic orthosis, a non-invasive brain-computer interface (BCI), and a virtual reality (VR) display. The goal of this trial is to advance stroke rehabilitation by exploring the potential benefits of these cutting-edge technologies.

Key Research Questions:

Efficacy: Does the new simulator significantly improve arm function compared to standard rehabilitation techniques?

BCI Technology: Which approach - motor imagery of only the paretic arm or both the paretic and healthy arm - yields greater functional improvements?

VR Contribution: How does the integration of VR enhance rehabilitation outcomes?

Safety and Tolerability: What potential side effects or adverse events may arise from using the new simulator?

Participants who have suffered a stroke will undergo a standard rehabilitation course, during which 10-12 sessions will take place using the innovative simulator: a robotic device moves a patient's paralyzed arm at the command of a non-invasive brain-computer interface to perform a game task resembling real-life activities, augmented by a virtual reality display.

Researchers will assess the impact of the new technology on arm function to determine its efficacy in promoting recovery.

03

Conditions studied

  • Stroke
  • Stroke Acute
  • Stroke with Hemiparesis
  • Stroke, Acute
  • Stroke, Acute, Ischemic
  • Stroke, Ischemic

Browse trials for

Keywords

  • Stroke
  • Rehabilitation
  • Brain-Computer Interface
  • Motor Imagery
  • Robotics
  • Virtual Reality
  • Neurofeedback
04

In context

Ischemic Stroke Reclassified

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

This study's planned enrollment of 44 is below the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.

Browse Ischemic Stroke studies →

Lead sponsor

This is the only study on the registry with Neurotechnika as lead sponsor.

Compared within Ischemic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written .
  • Age 18 to 80 years at the time of stroke onset.
  • Early rehabilitation period (up to 6 months post-stroke).
  • Diagnosis of acute cerebrovascular accident confirmed by MRI or CT.
  • Upper limb paresis severity between 0 and 3 on the 6-point Medical Research Council (MRC) muscle strength scale.
  • Ability and willingness to comply with the study protocol.
  • Demonstrated motivation for rehabilitation.

Exclusion criteria

Exclusion Criteria:

  • scale (MoCA) score less than 10 points.
  • Hamilton Depression Rating Scale (Ham-D) score greater than 18 points.
  • Modified Rankin Scale (mRS) score greater than 4 points.
  • Pre-existing conditions that cause decreased muscle strength or increased muscle tone in the upper limbs (e.g., cerebral palsy, traumatic brain injury) or rigidity (e.g., Parkinson's disease, contractures).
  • Advanced arthritis or significant limitation of upper limb range of motion.
  • Absence of part of the upper limb due to amputation for any reason.
  • Any medical condition that may affect the conduct of the study or patient safety (e.g., mental illness).
  • Alcohol abuse or recreational drug use within the 12 months preceding the study.
  • Use of experimental medications or medical devices within the 30 days preceding the study.
  • Inability to comply with research procedures, as determined by the researcher.
  • The severity of the patient's condition, based on neurological or physical status, does not permit full rehabilitation.
  • Visual acuity less than 0.2 in the weakest eye according to the Sivtsev visual acuity chart.
  • Unstable angina and/or heart attack within the 30 days preceding the study.
  • Recurrent stroke.
  • Uncontrolled arterial hypertension.
  • Ataxia.
  • Presence of a pacemaker and/or other implanted electronic devices.
  • Use of muscle relaxants.
  • Peripheral neuropathy.
  • Coexisting diseases in an exacerbation or decompensated stage requiring active treatment.
  • Allergic reactions or other skin lesions at the EEG electrode application sites at the time of the study.
  • Acute urinary tract infections.
  • Acute thrombophlebitis.
  • Any form of epilepsy.
  • Benign and malignant neoplasms.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
44 participants (estimated)

Study arms

  • Active comparator
    Control

    The Control group receives a standard course of intervention (14-21 days) as prescribed by the attending physician, in accordance with the standards of the Ministry of Health of the Russian Federation for the provision of medical care to people who have suffered a stroke.

    Procedure: Standard course

  • Experimental
    MI+VR

    In addition to the standard course of intervention, the MI+VR group undergoes 10-12 sessions using a novel simulator involving the paretic arm with immersion in virtual reality.

    Device: Neurorehabilitation simulator · Procedure: Standard course

  • Experimental
    MI2+VR

    In addition to the standard course of intervention, the MI2+VR group undergoes 10-12 sessions using a novel simulator involving both arms (healthy and paretic) with immersion in virtual reality.

    Device: Neurorehabilitation simulator · Procedure: Standard course

  • Experimental
    MI2

    In addition to the standard course of intervention, the group MI2 undergoes 10-12 sessions using a novel simulator involving both arms (healthy and paretic) without immersion in virtual reality, using a computer display instead.

    Device: Neurorehabilitation simulator · Procedure: Standard course

Interventions

  • DeviceNeurorehabilitation simulator

    The participant must complete a mental task - imagine the movement of his arm. If successful, the robotic simulator moves the paralyzed limb.

  • ProcedureStandard course

    The participant receives a standard course of intervention as prescribed by the attending physician in accordance

07

What researchers measure

Primary outcomes

  1. FMA-UE A-D

    The Fugl-Meyer Assessment for Upper Extremity, parts A-D (FMA-UE A-D) evaluates a patient's motor function, with scores ranging from 0 (indicating the most severe impairment) to 66 (indicating no impairment). Details available at https://www.gu.se/en/neuroscience-physiology/fugl-meyer-assessment.

    Time frame: From enrollment to the end of treatment at 2-3 weeks

  2. ARAT

    The Action Research Arm Test (ARAT) evaluates a patient's ability to handle objects of various sizes, weights, and shapes, making it a specific measure of arm-related activity limitations. Scores range from 0 (indicating the most severe impairment) to 57 (indicating no impairment). Details available at https://strokengine.ca/en/assessments/action-research-arm-test-arat.

    Time frame: From enrollment to the end of treatment at 2-3 weeks

Secondary outcomes

  1. NIHSS

    Dynamics according to the National Institutes of Health Stroke Scale (NIHSS) that assesses a stroke patient's neurological impairment and degree of recovery for patients with stroke in the range from 0 (no impairment) to 42 (very severe impairment). Details available at https://strokengine.ca/en/assessments/nihss.

    Time frame: From enrollment to the end of treatment at 2-3 weeks

  2. Ashworth

    Dynamics according to the Ashworth Spasticity Scale that assesses a patient's spasticity in the range from 0 (no increase in muscle tone) to 4 (affected part rigid in flexion or extension). Details available at https://www.sralab.org/rehabilitation-measures/ashworth-scale-modified-ashworth-scale.

    Time frame: From enrollment to the end of treatment at 2-3 weeks

  3. RMI

    Dynamics according to the Rivermead Mobility Index (RMI) that assesses a patient's functional abilities such as gait, balance, and transfers in the range from 0 (worst mobility performance) to 15 (best mobility performance). Details available at https://strokengine.ca/en/assessments/rivermead-mobility-index-rmi.

    Time frame: From enrollment to the end of treatment at 2-3 weeks

  4. MRS

    Dynamics according to the Modified Rankin Scale (MRS) that assesses a patient's level of functional independence in the range from 0 (no symptoms) to 5 (severe disability). Details available at https://strokengine.ca/en/assessments/modified-rankin-scale-mrs.

    Time frame: From enrollment to the end of treatment at 2-3 weeks

  5. SF-36

    The SF-36 is a multi-purpose survey designed to capture adult patients' perceptions of their own health and well-being. Scores range from 0 (maximum disability) to 100 (no disability). Details available at https://nexusipe.org/advancing/assessment-evaluation/short-form-sf-36-health-survey.

    Time frame: From enrollment to the end of treatment at 2-3 weeks

Other outcomes

  1. ICF

    The International Classification of Functioning, Disability and Health, known more commonly as ICF, is a classification of health and health-related domains. The ICF will be used to assess the impairment of body functions resulting from a stroke. Details available at https://www.who.int/standards/classifications/international-classification-of-functioning-disability-and-health

    Time frame: From enrollment to the end of treatment at 2-3 weeks

08

Study locations

1 of 1 sites recruiting
  • Samara Regional Clinical Hospital named after V.D. Seredavin
    Samara, Samara Region 443095, Russian Federation
    Recruiting
    • Alexander Zakharov, Ph.D. · Contacta.v.zaharov@samsmu.ru · +79171620301
    • Alexander Zakharov, Ph.D. · Contact
09

References and documents

Individual participant data

Plan to share: No — Only authorized members of the research team will have access to individual participant data (IPD). The research team will not share any IPD with third parties. However, de-identified demographic and clinical data-such as treatment details, baseline characteristics, and outcome measures-will be made publicly available.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Jul 2025, 11 months after the start.

Of 80 industry-sponsored interventional studies with no phase under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's planned 11 months is below that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2024
First posted
Dec 31, 2024
StartActual
Aug 27, 2024
Primary completionEst.
Jul 2025
CompletionEst.
Jul 2025
Last update
Jan 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06753006
Lead sponsor
Neurotechnika
Collaborators
Samara State Medical University, Samara Regional Clinical Hospital V.D. Seredavin
Responsible party
Sponsor
First posted
Dec 31, 2024
Start date
Aug 27, 2024
Primary completion
Jul 2025 (estimated)
Completion
Jul 2025 (estimated)
Last update
Jan 1, 2025

Study contacts

Vladimir Bulanov
Contact
vb@ntech.team
+79272081176
Alexander Zakharov, Ph.D.
Contact
+79171620301
Alexander Zakharov, Ph.D.
principal investigator · Samara State Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion